Literature DB >> 29316596

van Neck-Odelberg Disease: A 3.5-Year Follow-Up Case Report and Systematic Review.

Patrick J Mixa1, Frank A Segreto1, Hiram Luigi-Martinez1, Bassel G Diebo1, Qais Naziri1, Srinivas Kolla2, Aditya V Maheshwari1.   

Abstract

V an Neck-Odelberg disease (VND) is a benign skeletal overgrowth of the ischiopubic synchondrosis (IPS) in prepubescent patients. There is a paucity of long-term follow-up data and reviews on management decision-making. We report on a 15-year-old female, with a history of sickle-cell disease (HbSS), presenting with unilateral groin pain. Patient's physical examination, radiographs, and a literature-review determined a diagnosis of VND. Conservative treatment was issued. Clinical symptoms resolved at three months, followed by complete lesion resolution at three years. Additionally, a search of Medline (PubMed), EMBASE, and OVID databases was performed. Reports including VND/IPS diagnosis, treatment, or follow-up decisions were identified. Systematic-review found 17 relevant articles, reporting on 29 patients. Patients presented with groin (51.7%) or buttock (20.7%) pain, and were diagnosed using X-ray (n=23) and magnetic resonance imaging (MRI) (n=17). Twenty-five patients were treated conservatively, with two (8.0%) reports of surgical intervention. Average follow-up was 6.25 months. Our case report and systematic-review support conservative treatment for VND.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29316596

Source DB:  PubMed          Journal:  Surg Technol Int        ISSN: 1090-3941


  1 in total

1.  Invasive diagnostic and therapeutic measures are unnecessary in patients with symptomatic van Neck-Odelberg disease (ischiopubic synchondrosis): a retrospective single-center study of 21 patients with median follow-up of 5 years.

Authors:  Kristian Nikolaus Schneider; Lukas Peter Lampe; Georg Gosheger; Christoph Theil; Max Masthoff; Robert Rödl; Björn Vogt; Dimosthenis Andreou
Journal:  Acta Orthop       Date:  2021-02-04       Impact factor: 3.717

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.